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Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193S188recorded data that includes blood pressure (BP) readings 4
weeks before the transplant and then at days 0, 30,100 and
180. Other data includes GFRwhich is calculated by using the
Cockcroft Gault formula at the same intervals, sub-type of
MM and Durie-Salmon stage at diagnosis, disease response
to therapy, BMI at baseline; and other comorbidities such as
diabetes, hyperlipedemia and coronary artery disease.
Statistical analyses were performed using the statistical
package of SPSS version 18. All P-values were 2-sided.
Results: In this study 184 patients were included. The sample
demographics at baseline arepresented inTable 1. Association
between BP stages and disease status before ASCT and at day
0was statistically signiﬁcant (p¼.025 , X2¼14.408); therewas
no statistically signiﬁcant association between stages of HTN
at 0 , 30,100 and180daysafter theASCT in regards to age , race
or gender. Mean Systolic and diastolic BP-value showed no
statistically signiﬁcant difference at the same intervals
respectively. In addition, there was no correlation between
stages of HTN, and stages or type ofMM. The only statistically
signiﬁcant association between chronic kidney disease (CKD)
stages and BP stages was at day 0 (day ASCT infused) (P¼.032,
X2 ¼26.670. The association between CKD stages and diseaseTable 1
Demographic characteristics of the simple
Patient Characteristics Number (%)
Gender
Male 100 (54%)
Median age years (range) 59 (33-73)
Race
White 138 (75%)
African-American 41 (22%)
Other 5 (3%)
Marital status
Never married 18 (10%)
Now married 127 (69%)
Separated 13 (7%)
Widowed 6 (3%)
Divorced 20 (11%)
Health insurance
Medicare 180 (98%)
Other 4 (2%)
BMI
Normal 42 (23%)
Overweight 64 (35%)
Obese 42 (23%)
Severely obese 36 (19%)
BP stage
Normal 32 (17%)
Prehypertension 78 (43%)
Stage 1 HTN 64 (35%)
Stage 2 HTN 19 (5%)
CKD stage
1 60 (33%)
2 82 (45%)
3A 24 (13%)
3B 10 (5%)
4 5 (3%)
5 3 (1%)
Myebma stage
IA 17 (19%)
IIA 25 (14%)
IIIA 130 (71%)
IIIB 12 (6%)
Disease status
VGPR 65 (35%)
PR 57 (31%)
CR 26 (14%)
SD 18 (10%)
PD 16 (9%)
SCR 2 (1%)
Melphalan dose
200 mg 140 (76%)
140 mg 44 (24%)status at 100 days aftermelphalanwas statistically signiﬁcant
(P¼.043, X2¼25.568). The associations betweenBP stages and
BMI stages were borderline or statistically signiﬁcant at 30
days (P¼.054 and X2¼16.665), 100 days (P¼.026 and
X2¼18.947) and 180 days(P¼.001, X2¼27.120).
Conclusion: There was no direct effect of ASCT on blood
pressure improvement. Other factors such as BMI and
disease status at baseline appear to play more roles on Bp
control. Majority of our patient were transplanted at early
stages of (CKD) which can explain the result. We suggest
a prospective study that evaluates the impact of ASCT in MM
patients with high BP.
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No standard method for HSC mobilization prior to autolo-
gous stem cell transplant (ASCT) exists. We performed
a retrospective analysis on consecutive adult patients (pts)
undergoing mobilization for ASCT between 1/2009 and 1/
2012 to compare efﬁcacy of mobilization method and trans-
plant outcome.Method ofmobilizationwas per the discretion
of the attending physician. Chemotherapy andG-CSF (Chemo/
G)were used if therapyor cytoreductionwas necessary for the
underlying malignancy. Per institutional guideline cytokine
onlymobilizationusedG-CSF (G)10ug/kgdailywithapheresis
startingonday5andplerixafor (G/P)0.24mg/kgwasaddedon
day 4 if the peripheral bloodCD34+ cells/ulwas< 15. A total of
343 pts underwent 362 attempts at collection, 192 with G/P,
135 with G alone, and 35 after chemo/G. The median days of
apheresis for all three groups was 2 (range 1-4) and the
number of cumulative CD 34 cells collected after mobilization
was5.7(0-19), 6.8 (1.9-20.9), and6.3(0-19)million/kg in theG/
P, G, and chemo/G groups, respectively (p¼NS). Failure to
mobilize CD34 cells was deﬁned as never reaching 10 or
greater peripheral blood CD34+ cells/ul or collecting less than
2millionCD34+ cells/kg. Per institutional guideline 192 of 327
collections (59%) starting with G-CSF alone required the
addition of plerixafor. Nine of 192 collections (4.6%) in the G/P
group failed tomobilize and 2were rescuedwith a secondG/P
mobilization. Twelve of 35 collections (34%) in the chemo/G
group failed to mobilize and 8 were subsequently mobilized
adequately with G/P. Overall, 11/343 (3.2%) pts failed to
mobilize adequate CD34+cells. Engraftment and day 100
transplant outcomes were not different between the groups.
In conclusion, themethodofmobilizingHSC for ASCTdoes not
seem to affect clinical outcome, pts that fail mobilization after
chemo/G for treatment of active disease or cytoreduction can
be remobilizedwithG/P, andour current institutionalprotocol
to beginmobilizationwithG alone and add plerixafor on day 4
as described above allows a high rate of mobilization success.
Further prospective studies are needed to assess pharmacoe-
conomic and quality of life issues related to HSC mobilization.
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